MOUNTAIN VIEW, Calif. — May 4th, 2026 — LifeScience PLUS, Inc. announced FDA 510(k) clearance for BloodSTOP® iX Trauma Matrix for expanded use in the external temporary treatment of severely bleeding wounds, such as surgical wounds (operative, postoperative, dermatological, etc.) and traumatic injuries.
“This FDA clearance is a major milestone for LifeScience PLUS and for medical professionals treating severely bleeding wounds,” said Vicky Feng, CEO. “BloodSTOP iX Trauma Matrix gives surgeons and emergency care teams a powerful, easy-to-use tool to help control severe bleeding when rapid action is critical. We believe this clearance expands the potential for Trauma Matrix to support care across a broader range of severe injuries, benefit more patients in both prehospital and hospital wound care, and save more lives.”
BloodSTOP iX Trauma Matrix is designed for rapid, intuitive use in high-pressure bleeding situations where timely hemorrhage control is critical, including burn, trauma, and blast wound care in mass casualty scenarios. Upon contact with blood and exudates, the dressing absorbs fluid, transforms into a sticky gel, and adheres to the wound. Made from etherified sodium carboxymethyl cellulose (eCMC), the plant-based product is biocompatible and contains no human or animal biological substances and no medicinal substances.
Clinically, BloodSTOP iX Trauma Matrix has demonstrated meaningful value in damage control surgeries, where severe bleeding management is critical. Use of the product has been associated with significant reductions in blood utilization, fewer postoperative complications, shorter operative times, and broader clinical impact across severe injury cases.